DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
5.92
-0.30 (-4.82%)
At close: Nov 7, 2025, 4:00 PM EST
6.03
+0.11 (1.86%)
After-hours: Nov 7, 2025, 6:00 PM EST
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
306.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DMAC News
- 1 day ago - DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 - Business Wire
- 5 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference - Business Wire
- 3 months ago - DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia - Seeking Alpha
- 3 months ago - DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 3 months ago - DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Business Wire